Please Wait.....
Report
Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Report and Forecast 2023-2031
Market Report I 2023-04-11 I 147 Pages I EMR Inc.
Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Report and Forecast 2023-2031
Global Attention Deficit Hyperactivity Disorder (ADHD) treatment Market Outlook
The growth of the global attention deficit hyperactivity disorder (ADHD) treatment market is driven by the prevalence of ADHD. The market attained at value of USD 20.2 billion in 2022. It is further expected to grow at a CAGR of 5.5% during the forecast period of 2023-2031 to attain a value of about USD 32.6 billion by 2031, driven by the launch of various new drugs and awareness of the disease among people.
Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market: Introduction
The global ADHD treatment market report by Expert Market Research provides an in-depth analysis of the market and its segments. ADHD is a neurodevelopmental disorder that affects a significant percentage of the global population. The lack of effective treatments for ADHD has been a major challenge for healthcare providers and researchers worldwide. The report covers the market for ADHD treatment and provides a detailed analysis of the market size, growth, and trends.
The ADHD treatment market is expected to witness significant advancements in the coming years. The development of novel therapies, such as non-stimulant medications and digital therapeutics, and the increasing focus on personalized medicine are likely to drive the growth of the market. Additionally, the expansion of healthcare infrastructure in emerging economies and the increasing demand for advanced diagnostic tools and treatment options are expected to create lucrative opportunities for the market players.
Moreover, the growing adoption of telemedicine and digital health technologies may provide new avenues for the management and treatment of ADHD, potentially improving patient outcomes and reducing healthcare costs. As a result, the global ADHD treatment market is expected to continue its growth trajectory throughout the forecast period, offering numerous opportunities for key players and investors in the industry.
Attention Deficit Hyperactivity Disorder (ADHD) Epidemiology
The global epidemiology of ADHD varies based on factors such as age, gender, and geographic location. ADHD is one of the most common neurodevelopmental disorders in childhood, and it may persist into adulthood. The global prevalence of ADHD is estimated to be approximately 5-7%, with over 60 million people affected worldwide.
The ADHD treatment market is highly competitive, with numerous pharmaceutical companies operating in the market. The lack of effective treatments for ADHD has led to the emergence of many companies focusing on the development of innovative therapies for this disorder.
Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Segmentations
The market can be categorised into drug, treatment type, demographic, treatment channel, distribution channel, and major region.
Market Breakup by Drug
- Stimulant
? Amphetamine
? Methylphenidate
? Dextroamphetamine
? Dexmethylphenidate
? Lisdexamfetamine Dimesylate
- Non-Stimulant
? Atomoxetine
? Bupropion
? Guanfacine
? Clonidine
Market Breakup by Treatment Type
- Psychotherapy Treatment
? Behavioural Therapy
? Cognitive Behavioural Therapy
? Interpersonal Psychotherapy
? Family Therapy
- Education or Training
? Parent Management Training
? Social Skills Training
? School Based Interventions
Market Breakup by Demographic
- Adult
- Paediatric
Market Breakup by Treatment Channel
- Public
- Private
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Market Breakup by Region
- North America
? United States of America
? Canada
- Europe
? United Kingdom
? Germany
? France
? Italy
? Others
- Asia Pacific
? China
? Japan
? India
? ASEAN
? Australia
? Others
- Latin America
? Brazil
? Argentina
? Mexico
? Others
- Middle East and Africa
? Saudi Arabia
? United Arab Emirates
? Nigeria
? South Africa
? Others
Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Scenario
North America dominates the ADHD treatment market, followed by Europe and the Asia Pacific. The high prevalence of ADHD in North America, coupled with the favourable reimbursement policies, is driving the growth of the market in the region. Europe is also a significant market for ADHD treatment, with the presence of key players and increasing investment in research and development activities.
The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing awareness about ADHD and the rising healthcare expenditure in the region.
The market is highly fragmented, with numerous small and mid-sized companies operating in the market. The lack of effective treatments for ADHD has led to the emergence of a large number of companies focusing on the development of innovative therapies for this disorder.
The ADHD treatment market can be categorized based on drug class, distribution channel, and region. The market for non-stimulant medications is expected to grow significantly during the forecast period, driven by the increasing adoption of these drugs for the treatment of ADHD. The hospital pharmacies segment dominates the market, followed by retail pharmacies and online pharmacies. The high adoption of hospital pharmacies is driven by the availability of a wide range of drugs and the presence of trained healthcare professionals.
Key Players in the Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market
The report gives an in-depth analysis of the key players involved in the attention deficit hyperactivity disorder (ADHD) treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- Takeda Pharmaceutical Company Limited
- Aytu BioPharma, Inc.
- Eli Lilly and Company
- Pfizer Inc.
- Noven Pharmaceuticals Inc.
- Alcobra Ltd.
- Supernus Pharmaceuticals, Inc.
- Johnson & Johnson Services Inc.
- Novartis AG
- Curemark, LLC
- Impax Laboratories, LLC
- GlaxoSmithKline Plc
- Neos Therapeutics, Inc.
- Highland Therapeutics Inc.
- Advanz Pharmaceutical Corp.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Attention Deficit Hyperactivity Disorder (ADHD) Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials Synopsis
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.1.1 Timelines from Drug Development to Commercial Launch
6.2.1.2 New Drug Application
6.2.1.2.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
6.4.1.1 US FDA
6.4.1.2 EU EMA
6.4.1.3 INDIA CDSCO
6.4.1.4 JAPAN PMDA
6.4.1.5 Others
7 Challenges and Unmet Need
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market
8.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Overview
8.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Historical Value (2016-2022)
8.2.1.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Forecast Value (2023-2031)
8.3 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market by Drug
8.3.1 Market Overview
8.3.1.1 Stimulant
8.3.1.1.1 Amphetamine
8.3.1.1.2 Methylphenidate
8.3.1.1.3 Dextroamphetamine
8.3.1.1.4 Dexmethylphenidate
8.3.1.1.5 Lisdexamfetamine Dimesylate
8.3.1.2 Non-Stimulant
8.3.1.2.1 Atomoxetine
8.3.1.2.2 Bupropion
8.3.1.2.3 Guanfacine
8.3.1.2.4 Clonidine
8.4 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market by Treatment Type
8.4.1 Market Overview
8.4.1.1 Psychotherapy Treatment
8.4.1.1.1 Behavioural Therapy
8.4.1.1.2 Cognitive Behavioural Therapy
8.4.1.1.3 Interpersonal Psychotherapy
8.4.1.1.4 Family Therapy
8.4.1.2 Education or Training
8.4.1.2.1 Parent Management Training
8.4.1.2.2 Social Skills Training
8.4.1.2.3 School Based Interventions
8.5 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market by Demographic
8.5.1 Market Overview
8.5.1.1 Adult
8.5.1.2 Pediatric
8.6 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market by Treatment Channel
8.6.1 Public
8.6.2 Private
8.7 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market by Distribution Channel of Drugs
8.7.1 Market Overview
8.7.1.1 Retail Pharmacy
8.7.1.2 Hospital Pharmacy
8.8 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market by Region
8.8.1 Market Overview
8.8.1.1 North America
8.8.1.2 Europe
8.8.1.3 Asia Pacific
8.8.1.4 Latin America
8.8.1.5 Middle East and Africa
9 North America Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Canada
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Germany
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 France
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Italy
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
10.6 Others
11 Asia Pacific Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Japan
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 India
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 ASEAN
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Australia
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
11.7 Others
12 Latin America Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3 Argentina
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4 Mexico
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
12.5 Others
13 Middle East and Africa Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4 Nigeria
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
13.6 Others
14 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter's Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Takeda Pharmaceutical Company Limited
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Aytu BioPharma, Inc.
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Eli Lilly and Company
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Pfizer Inc.
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Noven Pharmaceuticals Inc.
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Alcobra Ltd.
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Supernus Pharmaceuticals, Inc.
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 Johnson & Johnson Services Inc.
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Novartis AG
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Curemark, LLC
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Impax Laboratories, LLC
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
15.12 GlaxoSmithKline Plc
15.12.1 Company Overview
15.12.2 Product Portfolio
15.12.3 Demographic Reach and Achievements
15.12.4 Mergers and Acquisitions
15.12.5 Certifications
15.13 Neos Therapeutics, Inc.
15.13.1 Company Overview
15.13.2 Product Portfolio
15.13.3 Demographic Reach and Achievements
15.13.4 Mergers and Acquisitions
15.13.5 Certifications
15.14 Highland Therapeutics Inc.
15.14.1 Company Overview
15.14.2 Product Portfolio
15.14.3 Demographic Reach and Achievements
15.14.4 Mergers and Acquisitions
15.14.5 Certifications
15.15 Advanz Pharmaceutical Corp.
15.15.1 Company Overview
15.15.2 Product Portfolio
15.15.3 Demographic Reach and Achievements
15.15.4 Mergers and Acquisitions
15.15.5 Certifications
16 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market- Drug Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security